Who is sponsoring NCT00659178?

NCT00659178 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00659178?

Interventions in NCT00659178: SB-485232 (interleukin 18), pegylated liposomal doxorubicin.

What condition does NCT00659178 study?

NCT00659178 studies Neoplasms, Ovarian.

Is NCT00659178 still recruiting?

NCT00659178 is currently completed. Last updated 21 July 2017.

Last reviewed 2017-07-21 · How we verify

NCT00659178

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer

Completed Phase 1 Last updated 21 July 2017

What this trial tests

Phase 1 trial testing SB-485232 (interleukin 18), pegylated liposomal doxorubicin in Neoplasms, Ovarian in 15 participants. Completed in 18 February 2011.

Timeline

18 June 2008

Primary endpoint
18 February 2011

18 February 2011

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	18 June 2008
Primary completion	18 February 2011
Estimated completion	18 February 2011
Sites	3 locations across United States

Drugs / interventions tested

SB-485232 (interleukin 18), pegylated liposomal doxorubicin — full drug profile →

Conditions studied

Neoplasms, Ovarian — all drugs for Neoplasms, Ovarian →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

18 and older, female only, with Neoplasms, Ovarian. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to identify a dose of SB-485232 which is safe, tolerable and biologically active when used in combination with pegylated liposomal doxorubicin (Doxil) in patients with epithelial ovarian cancer. This study will use a standard treatment regimen of pegylated liposomal doxorubicin (Doxil) in combination with rising doses of SB-485232. The dose selected from this study will be used in a future studies to evaluate the efficacy of this combination.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration.
Doyle SL, Ozaki E, Brennan K, Humphries MM, et al · · 2014 · cited 79× · PMID 24695684 · DOI 10.1126/scitranslmed.3007616
Trial Watch: Immunostimulatory cytokines.
Vacchelli E, Galluzzi L, Eggermont A, Galon J, et al · · 2012 · cited 70× · PMID 22754768 · DOI 10.4161/onci.20459
Involvement of inflammasomes in tumor microenvironment and tumor therapies.
Zhang Z, Li X, Wang Y, Wei Y, et al · · 2023 · cited 55× · PMID 36932407 · DOI 10.1186/s13045-023-01407-7
Inflammation in cancer: therapeutic opportunities from new insights.
Xie Y, Liu F, Wu Y, Zhu Y, et al · · 2025 · cited 53× · PMID 39994787 · DOI 10.1186/s12943-025-02243-8
Immunotherapy in ovarian cancer.
Mantia-Smaldone GM, Corr B, Chu CS. · · 2012 · cited 44× · PMID 22906947 · DOI 10.4161/hv.20738
Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy.
Wang T, Suita Y, Miriyala S, Dean J, et al · · 2021 · cited 33× · PMID 33918635 · DOI 10.3390/pharmaceutics13040520
Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.
Gralewska P, Gajek A, Marczak A, Rogalska A. · · 2024 · cited 21× · PMID 39125873 · DOI 10.3390/ijms25158304
Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy.
Xu T, Liu Z, Huang L, Jing J, et al · · 2022 · cited 15× · PMID 36532066 · DOI 10.3389/fimmu.2022.1057850

Verify or expand the search:

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00659178 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 21 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00659178.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing